During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

Frequent cystoscopy for monitoring nonmuscle-invasive bladder cancer (NMIBC) is burdensome and costly, prompting a search for alternatives.

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

Discover the latest updates to the EAU guidelines for muscle-invasive and metastatic bladder cancer in 2025. Learn more.

Learn all about Opdivo Qvantig (nivolumab/hyaluronidase-nvhy). It's a prescription injection used to treat certain types of cancer in adults.

This trial is looking at adding BMS-986205 and nivolumab to chemotherapy before surgery for invasive bladder cancer.

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with or without prior neoadjuvant chemotherapy.

SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to ...

References “Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: additional efficacy outcomes including overall survival in patients with muscle-invasive bladder cancer ...

Adjuvant nivolumab after radical surgery can improve DFS and OS in patients with MIBC, results from the CheckMate 274 trial suggest.